Hannah Rickner

Hannah joined the Methods Development Lab (MDL) at the Broad Institute as a Research Scientist II in 2025. Her work centers on high-throughput, scalable single-cell CRISPR perturbation assay development. MDL aims to drive the creation of robust single-cell analysis tools for the research community. 

Hannah completed her PhD in Cell and Molecular Biology with a focus on neurodegenerative disease modeling using single-cell technology. She then joined Fluent Biosciences as a member of the research and development team. There, she helped develop the PIPseq single-cell CRISPR screening technology, which successfully transitioned to Illumina following its acquisition. 

Outside of assay development, Hannah is tackling DIY home projects and is an aspiring gardener. She aims to travel by camper van to a new U.S. state each year, picked randomly out of a hat.